PasitheaLogo.png
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position
January 08, 2024 07:59 ET | Pasithea
Pasithea Therapeutics unveils crystalline PAS-004, extending IP protection to 2045 for CNS disorder treatments.
PasitheaLogo.png
Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients
January 02, 2024 08:35 ET | Pasithea
Pasithea's IND for PAS-004, a novel MEK inhibitor, is FDA-approved for Phase 1 trials in advanced cancer, starting Q1 2024 with early results by Q3.
PasitheaLogo.png
Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023
December 28, 2023 17:00 ET | Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) adjourns stockholder meeting again to Dec 29 for voting on charter amendments, after partial adjournment on Dec 19.
PasitheaLogo.png
Pasithea Therapeutics Announces Results from 2023 Annual Meeting
December 19, 2023 17:19 ET | Pasithea
Disclosure related to the annual meeting of Pasithea Therapeutics (Nasdaq: KTTA)
PasitheaLogo.png
Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models
December 11, 2023 08:01 ET | Pasithea
Pasithea Therapeutics (Nasdaq: KTTA) announced positive preclinical efficacy in models conducted ahead of its planned Phase I, in-human trials in 1Q24.
PasitheaLogo.png
Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
November 29, 2023 16:27 ET | Pasithea
Pasithea Therapeutics adjourns 2023 annual meeting of stockholders.
PasitheaLogo.png
Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development
November 29, 2023 07:59 ET | Pasithea
Pasithea Therapeutics Discusses Outcome of Pre-IND Meeting with FDA for Clinical Development of its MEK inhibitor, PAS-004
PasitheaLogo.png
Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS
November 09, 2023 07:59 ET | Pasithea
Pasithea Tx (Nasdaq: KTTA) Selects Lead Development Candidate, Humanized mAb that Targets α5β1 Integrin for Treatment of both Sporadic and Familial ALS
PasitheaLogo.png
Pasithea Therapeutics Corp. Announces Final Results of Tender Offer
September 14, 2023 08:30 ET | Pasithea
PALO ALTO, Calif. and MIAMI, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research,...
PasitheaLogo.png
Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference
September 07, 2023 16:14 ET | Pasithea
-- Attendees may request 1 x 1 meeting with management at meetings@hcwco.com --  PALO ALTO, Calif. and MIAMI, Fla., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA)...